



Wearable Drug Delivery: Smart & Easy



## Disclaimer

---

This document was prepared by EOFLOW Co.,Ltd. (hereafter, the "Company") with the purpose of providing useful information through presentations to investors.

The "predictive information" included in this presentation has not been verified. This information represents the Company's predicted management status and financial performance with regard to the future, not the past. The statements include terms related to the future, such as 'expect', 'forecast', 'plan', 'anticipate', and '(E)'.

The 'predictive information' may be affected by future management and contains inherent uncertainty. Actual future performance may differ significantly from the 'predictive information' or implied information herein due to these uncertainties.

Furthermore, please note that this presentation has been prepared on the basis of information available to EOFLOW as of the current date and reflects the current market conditions as well as the Company's management direction. Any details are subject to change without prior notice due to changes in market conditions and operation strategies in the future.



The Company and its employees will not be liable for any losses incurred from utilizing the information contained in this presentation and other misdeeds including, but not limited to, negligence.

This presentation does not contain information that suggests an invitation to subscribe for shares or sales of shares. no part of this presentation may be the basis for making investment decisions or concluding a contract.

The material in this presentation may be used without any alteration for non-profit purposes only (citing the source is required), however unauthorized distribution, copying, and alteration of information shall be subject to legal penalty.



Live Your Life  
Without  
Sacrificing  
the Care



Chapter 1.  
Executive Summary

Chapter 2.  
Business Highlights

Chapter 3.  
Financials Highlights

Appendix





Chapter 1.

## Executive Summary

01 Business Performance and Financial Highlights

Investor Relations 2022



## 01. Business Performance and Finance Highlights

### Progress in Business and in Financials in 3Q

- Going global
    - EOPatch with Narsha App (AOS and iOS) Launched in Europe
    - Approval from the U.A.E. and Indonesia
    - Preparing to submit a 510(k) application to the US FDA for EOPatch
  - Direct Sales in Korea
    - Direct Sales in Korea; number of users increases to 580+ in Oct 2022
  - New Product
    - Announcement of a new breakthrough product R&D: 7-day 3ml "EOPatch 3.0"
    - EOPatch X T1D clinical study well under way
      - 76% enrollment rate (First patient enrolled in May 2022)
- + (New Biz) Investment in Ferrex Therapeutics for drug-device combination biz
- 3Q 2022 Revenue of 3.5 B Korean Won; compared to 0.3 B Won in 3Q, 2021; 916% increase from the same period last year







## Chapter 2

# Business Highlights

- 01 Diabetes Management Market Trends (1) (2)
- 02 Korea Market (1) (2) (3)
- 03 Global Market (1) (2) (3)
- 04 EOPatch Product Roadmap & Clinical Studies
- 05 World's First 7-Day Wearable Pump, EOPatch 3.0 (1) (2)
- 06 Facility Investment
- 07 Non-insulin Business Updates (1) (2)

Investor Relations 2022




## 01. Diabetes Management Market Trends (1) AID and Wearable

1. Paradigm shifts to Automated Insulin Delivery (AID; Global AID CAGR 42%; Insulin Pump CAGR 12%)

We are currently conducting a clinical study of AID pump; EOPatch X in Korea

2. Insulin pump market visibly shifting to wearable disposable market

### Global AID and Insulin Pump User



### AID Product in market




Source : Close Concerns, Internal

### EOFlow's product line-up for AID



#### EOPATCH X

- 2-Part Wearable Artificial Pancreas
- + 3<sup>rd</sup> party Glucose sensor



#### EOANCREAS


- Integrated Wearable Artificial Pancreas
- + Built-in Glucose Sensor



## 01. Diabetes Management Market Trends (2) Wearable


In CGM, overall market grows. With pump, Insulet is outgrowing everybody else (Tandem cannibalizes Medtronic, but what after this...?)

### [ CGM ]



2Q22	Revenue (millions)	YOY Change	Sequential Change	Market Share (by revenue)
Abbott	\$1,073	+19%	+8%	54%
Dexcom	\$696	+17%	+11%	35%
Medtronic	~\$222	+4%	-12%	11%
Senseonics	\$3.7	+12%	+49%	0.2%
Total	\$1,994	+16%	+6%	-

### [ Insulin Pump ]



2Q22	Revenue (millions)	YOY Change	Sequential Change	Market Share (by revenue)
Medtronic	~\$320	-11%	-7%	38%
Insulet	\$286	+18%	+6%	34%
Tandem	\$200	+16%	+14%	24%
Roche (est.)	~\$42	+13%	-4%	5%
Total	\$849	+5%	+2%	-



## 02. Korea Market (1) Sales Activities

Company's sales & marketing activities picking up speed after termination of sales contract with Korean partner, Huons  
Offering various events and programs to users, guardians and medical personnel to boost EOPatch brand awareness

- EOPatch free trial offer in August
  - Offered 4 patches to new patients free for trial
  - Recorded all-time high number of 316 participants

8월 이오패치 체험 신청자는 패치가 2+2!

### 이오패치 무료체험 여름방학 이벤트

여름방학을 맞아하여  
이오패치 무료체험 2+2 이벤트를 진행합니다.  
8월 한달동안 이오패치 체험 신청을 해주시는 모든분들께 이오패치를 더 오래 체험하실 수 있도록 패치 2개를 추가 증정합니다. 이오패치 사용을 희망하시는 고객님의 많은 참여 부탁드립니다.

**기간** 8월1일 ~ 8월31일

**대상** 이오패치 구매 이력이 없는 사용 희망자

**체험 구성품** 이오패치 스타터킷(패치2개) + 패치2개 추가증정

**신청방법** 이오패치 온라인 교육센터 홈페이지 (www.eopatch.com) 상단메뉴 'EO교육센터' > '체험 신청' 클릭

**체험문의** 070-5217-2034  
또는 이오패치 카카오톡 모바일 상담 채널

\*인술린 바이알과 용량 처방은 의료진과 상담하시기 바랍니다.

316  
Trial users  
"1 in 3 buys"

- EOPatch Togethering user gatherings
  - 120 existing and new users participated in September
  - Planning regional gatherings : Busan in 1Q. 2023

제1회 이오패치 사용자 모임  
이오패치 투게더링

이오패치를 사용하고 계시는 분들, 그리고 평소 이오패치를 사용해보고 싶으셨던 분들을 위하여 오프라인 모임을 준비했습니다.  
이번 모임을 통해 제품에 대한 궁금증을 풀고 서로 정보를 공유하는 알찬 시간이 되시기 바랍니다.

**일시** : 2022년 9월 24일 토요일 오후 2시

**대상**  
• 이오패치 사용자  
• 이오패치 사용을 희망하시는 분들  
※보호자 동반이 가능합니다

**장소**  
서울특별시 강남구 강남대로 340, 경원빌딩 3층 위클리이스 강남점 (신분당선 강남역 4번 출구 도보 3분)

**신청방법**  
• 카카오톡 접수 '이오패치 모바일 상담' 채널 참가 요청  
070, 5217, 2034  
• 온라인 접수 링크 접속 [https://forms.gle/PaTcLWIGEtbnAK29] 또는 QR코드 스캔하여 '참가 신청서' 작성 후 제출

※ 참가비용은 무료이며, 참가인원은 추첨을 통해 선정됩니다.

120  
Existing &  
New users

- EOPatch Symposium
  - Celebrating 1 year of EOPatch sales
  - Busan on Nov. 26 ~ 27

### EOPatch Symposium 2022

일시: 2022.11.26(토)~27(일) 장소: 롯데호텔 부산, 별墅 스위트 룸(42층)  
주최: EOWFLOW

#### PROGRAM

**Day 1 - November 26 (Sat)** 좌장: 박철영 (성균관의대)

16:30 - 16:40	Opening	
16:40 - 17:10	EOPatch, an Effective and Comfort Device in Patients with T2D requiring Insulin Treatment	연자: 문선준 (성균관의대)
17:10 - 17:40	Good to Great for T1DM : EOPatch	연자: 문준성 (영남의대)
17:40 - 18:00	Q&A and Discussion	
18:00 - 19:00	Dinner	

**Day 2 - November 27 (Sun)** 좌장: 박철영 (성균관의대)

08:00 - 08:10	Opening	
08:10 - 08:40	Glycemia control using CGM with or without EOPatch	연자: 홍준화 (울지대의대)
08:40 - 09:00	Q&A and Discussion	

50  
Medical  
staff

## 02. Korea Market (2) Sales Performance

Number of new users has increased by 78% since EOFlow's direct sales, August – October 2022

Establishing & expanding network of hospitals offering EOPatch service & product


### New user increase in numbers (78% ↑ monthly average)



### Increasing number of EOPatch-friendly Hospitals

Securing regional hospitals: New users can receive how-to-use trainings directly at the hospital;  
Users can purchase the product from 6 out of the 45 hospitals

### No. of Base Hospitals







## 02. Korea Market (3) EOPatch User Experience Survey & Repurchase Rate

Survey was conducted to identify satisfaction of EOPatch, N=169 complete (Patient N=78, Care Partner N=91)

How satisfied are you with your EOPatch pump?



Source : 3<sup>rd</sup> Party Global Research & Analytics (October 2022)




Source : internal sales data

### 03. Global Market (1) Europe

Officially launched EOPatch with Narsha app in September (both in AOS and iOS)

Making progress in tenders & securing reimbursement: should lead to increased user & sales base

- Direct Sales (General reimburse market) + Tender-based approach
- 7 tenders won so far
  - 3 countries, 7 cities : Italy (Lombardia, Palermo, Napoli, Abruzzo, Lazio), Greece (Cyprus), Sweden (Stockholm)
  - Awarded 25% ~ 100%
  - Patient enroll date : end of 2022 ~ early 2023
- 5 more tenders submitted so far; waiting for results
  - New countries, national tenders, etc.





### 03. Global Market (2) Europe Launch Status

Starting with an official product launch in Italy in September, Menarini speeds in product registration, reimbursement and launch

#### GlucoMen Day PUMP Launch Status

Country	Product Registration	Reimbursement	Product Launch
Italy	Registered	Tender-based	September
Belgium	Registered	Reimbursed	Waiting
Germany	Registered	Under negotiation	October
Greece	Registered	Under negotiation	November
Portugal	Registered	Under negotiation	Q1 2023
Sweden	Registered	Tender-based	October
Spain	Registered	Tender-based	October
UK	Registered	Under negotiation	Q1 2023
France	Registered	Under negotiation	Q3 2023
Netherlands	Registered	Under negotiation	May
Austria	Ongoing	Under negotiation	Under negotiation
<b>Total</b>	Registered in 10 Countries	Reimbursed in 4 Countries	Launched in 5 Countries

### 03. Global Market (3) US

Preparing for entry: emphasis is on establishing long-term global leadership


1. EOPatch2.0 FDA 510(k) filing within 2022
2. Engaged with several potential partners – global leaders
  - Several potential partnership discussions at varying stages
  - Hoping to finalize on partnership within the next 4-6 months
3. Focusing on differentiation strategies:
  - Weekly T1D (AP): better value; better compliance
  - 3ml for T2D: smart basal & bolus for T2D, with simple UI
4. Other development: non-insulin opportunity with Ferrex Therapeutics
  - \$7B+ opportunity
  - (Harvard/MGH drug IP) + (EOPatch continuous subcutaneous delivery)
  - Addressing iron overload issue while eliminating side effects



## 04. EOPatch Product Roadmap & Clinical Studies

Providing end-to-end smart care solution for people with diabetes

Aims to launch the world's first fully integrated wearable artificial pancreas (AP) system in 2025



### Product roadmap/Launch Schedule

- EOPatch & EOPatch 3.0

Ongoing post approval clinical study for T2D (21.2H ~ 22.2H)

3ml, 7-Day EOPatch 3.0 targeting T1D & T2D

- EOPatch X

Ongoing K-MFDS approval clinical study (started in Jan. 2022)

Product approval & market launch target: end of 2023

- CGMS

Secured world-class in-house CGM solution

Preparing a clinical study targeting 2025 launch (as a part of EOPatch X)

- EOPancreas (all-in-one wearable AID)

Under development with in-house sensor solution

\* Product Road Map

## 05. World's First 7-Day Wearable Pump, EOPatch 3.0 (1)

The smallest and lightest wearable pump made possible for increased user compliance


Prototypes built & tested successfully

- Increase insulin reservoir size (2ml → 3ml) + Runs for up to 7 days
- Serving T1D – Lower cost & improve compliance (weekly routine)
- Serving T2D - Severe T2D patients often require more insulin and need simpler user interface

22% larger in size and 20% heavier in weight


### Current EOPatch

- 49.5 x 39 x 14.5 (mm)
- 26g



### New EOPatch 3.0

- 57.3 x 41.3 x 14.5 (mm)
- 30g




- EOPatch 3 prototype runs 7 days continuously with a 3ml reservoir
- Based on the ultra-low-power, high-performance pumping technology
- Successfully completed biocompatibility and toxicity tests on all major fast acting insulin products (1H, 2022)
- Cost increase will be 'small' over the current 3.5-day product



05. EOPatch 3.0 (2) Working Prototype Test Results

Functional Tests

Verified the system can run 6,000+ cycles (=3ml dispensing) and lasts 7-days (1 week drug delivery) with 3 batteries



## 06. Facility Investment

New lines at Gonjiam site: Target volumes of 825Ku/yr in 2022; 3.4M/yr in 2023; up to 6M/yr in 2024

Total investment ~20 billion Won/3.4Mu; ~33billion Won/6Mu

### Korea Site 1

Outsourced production base

#### Main Product

- EOPump

#### Production Capacity

- Annual 300K

### Korea Site 2

Outsourced production base

#### Main Product

- EOPatch

#### Production Capacity

- Annual 300K

### Gonjiam (1<sup>st</sup> stage)

Semi-Auto manufacturing line

- Production capacity: 825ku/year
- Under KGMP approval review > Dec. 2022 Approval expected
- Site construction for further expansion (~Apr. 2023)

### Gonjiam (2<sup>nd</sup> stage)

Full-Auto manufacturing line

- 1 new fully automated line capacity: 2.7M/year
- Addition of EOPump manufacturing line
- Additional registration of CE MDD manufacturing site; CE MDR, FDA planned
- The new line installation to be completed in 1H, 2023
- A second automated line installation planned for 2023

### Gonjiam New Site

Automation to reduce production cost and expand manufacturing capacity; located in Gonjiam (~1 hour drive from EOFLOW HQ)



Under construction from July 2021  
Completion expected by February 2023

#### Main Products

- EOPump and EOPatch

#### Production Capacity

- ~22.2H, 825k/year Capacity
- ~23.2H, 3.4M/year Capacity




## 07. Non-insulin Business Updates (1) Overview

Key Opportunities in Drug-Device Combo Biz: **Combining generic drug with EOFlow wearable platform,**  
**Accelerate commercialization of drug candidates with short half-life**

Two Key Axis: EOFlow Korea HQ as a diabetes & device platform operations


EOFlow, Inc. (US subsidiary) as a device-drug combo 'pharma' operations

EOFlow provides initial funding and its EOPatch wearable drug delivery system to SanPlena and Ferrex



## 07. Non-insulin Business Updates (2) Ferrex Therapeutics

- Our second drug –device product investment of U\$2.99mil owing 30% stake as the second largest shareholder
- Ferrex, founded by HS Choi, a Harvard Medical School professor and the inventor of nanochelator platforms, is developing innovative solutions for treatment of iron overload disorder
- Ferrex's new drug overcomes an off-target issue of current iron-chelation drugs which causes severe side effects: proved superior efficacy in animal tests.
- Given Novartis dominant market whose size is U\$ 5.2bil as of 2021 and will grow to U\$ 7.9bil by 2030, Ferrex's new drug can be a blockbuster



FDA-approved iron chelators	Deferoxamine (DFO)	Deferasirox (DFX)	Deferiprone (DFP)
Brand name	Desferal	Exjade, Jadenu	Ferriprox
FDA approval	1968	2005 / 2015	2011
Dose frequency	Infusion (8-24 h)	QD	TID/BID
Half-life	<2 h	8-16 h	2-3 h
Toxicity	Renal tox Hypotension <b>Tachycardia</b> Muscle pain	<b>GI bleeding</b> <b>Renal failure</b> <b>Liver failure</b> Cytop enia	<b>Neutropenia</b> Agranulocytosis Hepatic fibrosis <b>Infection</b>
Current Players	Novartis (Switzerland) , Apotex Inc. (Canada), Cipla (India), Sun Pharma (India), Natco Pharma (India)		



## Chapter 3. **Financial Highlights**

- 01 Q3 FY22 Income statement
- 02 Q3 FY22 Balance Sheet

Investor Relations 2022



## 01. Q3 FY22 Income statement (Consolidated)

Recorded 3Q 2022 revenue of 3.5 billion Korean Won, an increase of 916% from the prior year

(Korean Won in millions)	Q3 2021	Q2 2022	Q3 2022	YoY	QoQ
Revenue	343	664	3,481	+916.2%	+424.5%
Gross Margin	(251.5)%	(96.4)%	29.9%	+281.4%	+126.3%
SG&A % of Sales	1,819.9%	1,162.1%	263.0%	(1,556.9)%	(899.1)%
R&D % of Sales	649.7%	578.0%	109.7%	(540.0)%	(468.3)%
Operating Profit	(7,096)	(8,353)	(8,115)	(1,019)	238
Operating Margin	(2,071.4)%	(1,258.5)%	(233.1)%	+1,838.3%	+1,025.4%
Net Income	(7,197)	(9,745)	(5,525)	1,672	4,220
Diluted EPS (in Won)	(624)	(291)	(176)	448	115

Note : Based on K-IFRS consolidated financial statement standard; Korean Won in millions except for EPS

## 02. Q3 FY22 Balance Sheet (Consolidated)

Continue to maintain a strong balance sheet

(Korean Won in millions)	Q3 2021	Q2 2022	Q3 2022	YoY	QoQ
<b>Total Assets</b>	61,997	158,340	158,989	96,992	649
<b>Cash, Cash Equivalents and Other Current Financial Assets</b>	34,686	105,568	100,015	65,329	(5,553)
<b>Account Receivables, net</b>	532	4,085	5,784	5,252	1,699
<b>PP&amp;E</b>	13,405	20,264	23,420	10,015	3,156
<b>Investments</b>	6,458	9,553	9,695	3,237	142
<b>Total Debt</b>	39,546	44,088	46,552	7,006	2,464
<b>Short term debt</b>	920	35,038	35,845	34,925	807
<b>Long term debt</b>	35,637	4,966	6,390	(29,247)	1,424
<b>Equity</b>	22,451	114,252	112,437	89,986	(1,815)

Note : Based on K-IFRS consolidated financial statement standard



## Appendix

- 01 Company Overview
- 02 Brief Company History
- 03 Top-Tier Global Team
- 04 Clinical Partners & Advisors
- 05 Summary of Financial Statements (Consolidated)

Investor Relations 2022



Company Overview

Company Name	EOFlow Co., Ltd.
CEO	Jesse J. Kim (Kim, Jaejin)
Date Established	2011. 9. 27.
Date Listed	KOSDAQ 2020.09.14.
Paid-in Capital (owner's capital)	3 Billion Korean Won (122.7 Billion)
Employees	121
Main Business	Medical Device Manufacturing
Main Product	Wearable Insulin Pump
Headquarter Address	#H2202, 172 Dolmaro, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, Korea 13605
Website	www.eoflow.com

Mission Statement



Date	Award	By
2017.07	Grand Prize, First Beyond-TIPS Awards	MoSMB
2017.12	Grand Prize, TIPS Grand Convention IR Competition	MoSMB
2018.08	EOFlow, 'Top 100 Science Spinoffs'	Spinoff.com
2019.01	Integrated Wearable AP System, FDA Breakthrough Devices Designation awarded	FDA
2019.10	MedTech Outlook, '2019 Company of the Year' in Diabetes	MedTech Outlook
2019.10	Red Herring 'Top 100 Asia' award	Red Herring

### Fundamental Research Period

#### • 2011

University of Texas at Austin, EOP patent filed  
- Patents issued in the US, EU, Korea (in 2020)  
EOFlow Co., Ltd. Founded  
- Preliminary animal tests (TX)

#### • 2012

First government project  
- Key pump parameters investigated & improved

#### • 2013

UT IP license agreement signed  
- Gasless electroosmotic pump patent  
- Conditional, permanent license (exclusive for insulin)

#### • 2014

Insulin pump product spec defined  
- First working product prototype demonstrated

### Product Development Period

#### • 2015

Angel & Series-A closed (4B KRW)  
Pump module (EOPatch) working sample demonstrated  
Working controller sample developed & demo'd

#### • 2016

Relocate to SNUH's Healthcare Innovation Park  
First commercial-grade samples demonstrated V&V tests conducted  
Series-B closed (5.5B KRW)

#### • 2017

First production line ready; US subsidiary established;  
Signed up Korean sales partner (Huons)  
- EOPatch1, KMFDS approval (12.19.)  
- Integrated module sensor partner signed up (POCTech)  
- Integrated AP module selected by JDRF for funding

#### • 2018

TypeZero AP algorithm agreement signed  
Series-C closed (14B KRW)  
Selected for major government grant program (3.5B KRW)  
First animal tests completed (August)

### Commercialization & Growth Period

#### • 2019

FDA Breakthrough Device Designation award (January)  
Series-D closed (4B KRW)  
EOPatch2, KMFDS approval (06.27.)  
EU distribution agreement signed with Menarini (07.24.)  
Sensor partner (DexCom) cooperative agreement signed  
T1D coaching service agreement with MediPlus (11.27.)  
2019 Red Herring Top100 Asia finalist  
MedTech Outlook 2019 Company of the Year

#### • 2020

Mezzanine round closed (2.1B KRW)  
Listed in the Korean KOSDAQ market (09.14.)  
EOPatch Post-market clinical study result announced

#### • 2021

Issued convertible bonds (35B KRW)  
Started EOPatch Sales in Korea (04.22.)  
Received EU CE certification (05.24.)  
Secured production capacity in Gonjiam (07.30.)  
Indonesia distribution agreement signed with PT.PNS (12.08.)

#### • 2022

Chinese JV Sinoflow established in China (01.26.)  
Capital raise and 2:1 stock split (113B KRW)  
GCC distribution agreement signed with GulfDrug (03.30.)  
Received approval from the United Arab Emirates (07.15.)  
Started EOPatch (GlucoMen Day PUMP) Sales in Europe by Menarini (09.22.)  
Received approval from Indonesia (10.20.)

## 03. Top-Tier Global Team

A global team of experience & know-how  
Founded 2011; Currently 130+ employees in Korea & the US

MIT graduate with engineering background

First to commercialize low-power electroosmotic pump technology

Second to commercialize wearable disposable insulin pump

CEO with over 20 years of Silicon Valley startup experiences

**Jesse Kim**  
Founding CEO

- MIT, EECS
- Motorola, R&D
- Intel, Technical Marketing
- TeleCruz, Biz Dev





**Luis Malave**  
President, US



**30 years in medical device industry**  
(Early member & COO at Insulet)

First VP of Engineering, Insulet;  
MiniMed early member, Medtronic;  
Medical device startup CEO

**I. Welsford, Ph.D.**  
CTO



**RA(Regulator Affairs)expert; FDA, CE**  
(RA leader at Insulet)

Paylon Medical, RA/QA/CA SVP;  
Fujitsu Bioscience Group;  
Insulet, RA/QA/CA Director

**CJ Kim**  
COO



**Experienced technology entrepreneur**

KAIST Ph.D.,  
Samsung Advanced Institute of Technology;  
Samsung Display

**Richard H. An**  
CFO



**Management and finance specialists**

UC Berkeley MBA  
NH Investment&Securities, Mirae Asset  
Daewoo Securities, Rexpine Investment,  
Fugenbio, Korea Development Finance Corp.



Global Clinical Study & Research Partners



Diabetes-center



Juvenile Diabetes  
Research Foundation



St. Mary's  
Hospital



Seoul Asan Hospital



Severance  
Hospital



Seoul National Univ.  
Bundang Hospital



Samsung Seoul  
Hospital



**Dr. David Klonoff**  
Prof., UCSF; First AP clinical  
studies PI (Medtronic);  
Editor-in-Chief, Journal of  
Diabetes Sci. & Tech



**Prof. Kim, SI**  
Prof., Medical engr, Hanyang U.  
Chairman, Osong K-Bio Center  
Vice chairman, KHIR Center  
MD, Korea Science Foundation



**Prof. WJ Lee, MD**  
Endocrinologist,  
Seoul Asan Hospital



**Prof. Frank Park**  
Dean, Mech/Aero Engineering,  
Seoul National University;  
IEEE Transaction on Robotics,  
Editor-in-Chief



**Prof. JR Park, MD**  
Head of diabetes center,  
Seoul Asan Hospital;  
Secretary, KDA



**Prof. JH Cho, MD**  
Head of U-Health center,  
St. Mary's Hospital

## 05. Summary of Financial Statements (Consolidated)

### Consolidated Balance Sheet

Unit : million KRW

	2019	2020	2021	2022.3Q
Current assets	6,207	23,036	37,271	113,838
Non-current assets	3,810	6,117	25,389	45,151
<b>Total assets</b>	<b>10,018</b>	<b>29,153</b>	<b>62,660</b>	<b>158,989</b>
Current liabilities	1,179	1,796	3,261	38,764
Non-current liabilities	5,352	2,522	40,482	7,788
<b>Total liabilities</b>	<b>6,531</b>	<b>4,318</b>	<b>43,743</b>	<b>46,552</b>
Capital attributable to the parent company	3,487	24,835	18,248	112,218
Capital amount	934	1,126	1,175	3,030
Capital surplus	53,927	94,167	116,386	229,206
Other capital	819	1,034	2,640	3,406
Accumulated other comprehensive income	(57)	292	(419)	1,336
Deficiencies	(52,136)	(71,783)	(101,533)	(124,760)
Capital not-attributable to the parent company	-	-	669	219
<b>Total Equity</b>	<b>3,487</b>	<b>24,835</b>	<b>18,917</b>	<b>112,437</b>

Note : Based on K-IFRS consolidated financial statement standard

### Consolidated Income Statement

Unit : million KRW

	2019	2020	2021	2022.3Q (Accumulated)
Sales	-	22	693	5,094
Cost of Goods Sold	-	692	2,824	5,462
Gross Profit	-	(671)	(2,131)	(368)
Selling & Administrative Expenses	8,490	12,188	24,761	24,372
<b>Operating profit</b>	<b>(8,490)</b>	<b>(12,858)</b>	<b>(26,892)</b>	<b>(24,740)</b>
Non-Operating Profit	(125)	(25)	38	379
Financial Profit	(774)	(6,764)	(3,134)	612
Profit(Loss) before Tax	(9,389)	(19,647)	(29,988)	(23,749)
<b>Net income</b>	<b>(9,389)</b>	<b>(19,647)</b>	<b>(29,988)</b>	<b>(23,749)</b>

Note : Based on K-IFRS consolidated financial statement standard